Newton Fund - DEVELOPMENT OF DIFFERENTIATED PRODUCT CONCEPTS FOR INSULIN GLARGINE

Lead Participant: Arecor Limited

Abstract

Availability of low cost insulin products, particularly products that can be distributed and used outside the cold

chain is critical to developing an effective healthcare system that can deal with the rapidly increasing incidence

of diabetes. This project will combine the expertise and technologies of Arecor and Cadila Pharmaceuticals to

develop a innovative, low cost basal insulin product that can be distributed and used outside the cold chain. In

addition validated technology will be employed to extend the duration of action of insulin glargine with

beneficial consequences to the control of hypoglycaemia. The scope of the project will allow formulation

development and optimisation, stability testing and pre-clinical development. Following successful completion

of the project, the project partners will progress the asset into clinical development and commercialisation. The

final product, which will draw on Arecor’s proprietary formulation technologies and Cadila’s excellent track

record in therapeutic development and commercialisation, will represent an attractive commercial opportunity

as well as having a strong positive impact on the economic development and social welfare in India.

Lead Participant

Project Cost

Grant Offer

Arecor Limited, Cambridge, United Kingdom £423,770 £ 296,639

Publications

10 25 50